Accurate Wealth Management LLC Sells 10,006 Shares of Becton, Dickinson and Company $BDX

Accurate Wealth Management LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 80.2% during the 4th quarter, HoldingsChannel reports. The firm owned 2,472 shares of the medical instruments supplier’s stock after selling 10,006 shares during the period. Accurate Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $501,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 71.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after purchasing an additional 34,437 shares during the last quarter. Transcend Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after purchasing an additional 2,715 shares in the last quarter. Belpointe Asset Management LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter worth $650,000. Finally, Vanguard Group Inc. grew its stake in Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after buying an additional 147,041 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on BDX shares. Piper Sandler reiterated a “neutral” rating and issued a $170.00 price target (down from $205.00) on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Citigroup cut their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Argus decreased their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Jefferies Financial Group lowered their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Finally, Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $191.62.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,713 shares of company stock worth $536,881 over the last ninety days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.0%

Shares of BDX stock opened at $154.52 on Monday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a market capitalization of $44.00 billion, a PE ratio of 25.21, a P/E/G ratio of 11.20 and a beta of 0.24. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock’s 50-day simple moving average is $180.63 and its 200-day simple moving average is $187.60.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the company posted $3.43 earnings per share. The company’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Becton, Dickinson and Company announced that its board has approved a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.